In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Alnylam gets option to MIT's liposomal delivery IP

Executive Summary

In its second deal announced in the same day, Alnylam Pharmaceuticals (developing RNAi therapeutics) has been granted an option to license the Massachusetts Institute of Technology's liposomal systems for siRNA delivery.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Liposomes
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register